Login to Your Account



Genta’s Antisense Cancer Drug At Center Of $480M Aventis Deal

By Randall Osborne


Tuesday, April 30, 2002
Talk about “validation.” The buzzword often used in discussing deals fits perfectly Genta Inc.’s potential $480 million agreement with Aventis SA to develop the former’s drug Genasense (G3139), the first antisense oncology compound - already in multiple Phase III trials - to target the Bcl-2 protein and boost the effectiveness of chemotherapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription